Powell J, Kayesh R, Ballesteros-Perez A, Alam K, Niyonshuti P, Soderblom E
Pharmaceutics. 2024; 16(1).
PMID: 38258074
PMC: 10818623.
DOI: 10.3390/pharmaceutics16010063.
Mboni-Johnston I, Kouidrat N, Hirsch C, Weber A, Meissner A, Adjaye J
Int J Mol Sci. 2024; 25(1).
PMID: 38203251
PMC: 10779191.
DOI: 10.3390/ijms25010081.
Ishikawa R, Saito K, Misawa T, Demizu Y, Saito Y
Biomolecules. 2023; 13(6).
PMID: 37371582
PMC: 10296347.
DOI: 10.3390/biom13061002.
Brunet M, Pastor-Anglada M
Pharmaceutics. 2022; 14(9).
PMID: 36145503
PMC: 9503558.
DOI: 10.3390/pharmaceutics14091755.
Chu X, Chan G, Houle R, Lin M, Yabut J, Fandozzi C
AAPS J. 2022; 24(3):45.
PMID: 35314909
DOI: 10.1208/s12248-021-00677-8.
Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.
Magdy T, Jouni M, Kuo H, Weddle C, Lyra-Leite D, Fonoudi H
Circulation. 2021; 145(4):279-294.
PMID: 34874743
PMC: 8792344.
DOI: 10.1161/CIRCULATIONAHA.121.055801.
Breeding history and candidate genes responsible for black skin of Xichuan black-bone chicken.
Li D, Sun G, Zhang M, Cao Y, Zhang C, Fu Y
BMC Genomics. 2020; 21(1):511.
PMID: 32703156
PMC: 7376702.
DOI: 10.1186/s12864-020-06900-8.
Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models.
Kayesh R, Farasyn T, Crowe A, Liu Q, Pahwa S, Alam K
J Pharm Sci. 2020; 110(1):314-324.
PMID: 32590030
PMC: 7750294.
DOI: 10.1016/j.xphs.2020.06.016.
Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients.
Maples K, Maloy M, Devlin S, Lin A, DeRespiris L, Griffin M
Bone Marrow Transplant. 2020; 55(8):1687-1689.
PMID: 31937928
DOI: 10.1038/s41409-020-0785-9.
Immunomodulation as a Novel Strategy for Prevention and Treatment of spp. Infections.
Gestal M, Johnson H, Harvill E
Front Immunol. 2020; 10:2869.
PMID: 31921136
PMC: 6923730.
DOI: 10.3389/fimmu.2019.02869.
Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.
Farasyn T, Crowe A, Hatley O, Neuhoff S, Alam K, Kanyo J
J Pharm Sci. 2019; 108(10):3443-3456.
PMID: 31047942
PMC: 6759397.
DOI: 10.1016/j.xphs.2019.04.019.
Pharmacological Cyclophilin Inhibitors Prevent Intoxication of Mammalian Cells with Toxin.
Ernst K, Eberhardt N, Mittler A, Sonnabend M, Anastasia A, Freisinger S
Toxins (Basel). 2018; 10(5).
PMID: 29723951
PMC: 5983237.
DOI: 10.3390/toxins10050181.
Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.
Alam K, Crowe A, Wang X, Zhang P, Ding K, Li L
Int J Mol Sci. 2018; 19(3).
PMID: 29538325
PMC: 5877716.
DOI: 10.3390/ijms19030855.
Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.
Pahwa S, Alam K, Crowe A, Farasyn T, Neuhoff S, Hatley O
J Pharm Sci. 2017; 106(8):2123-2135.
PMID: 28373111
PMC: 5511785.
DOI: 10.1016/j.xphs.2017.03.022.
Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
Eley T, Garimella T, Li W, Bertz R
Clin Pharmacokinet. 2015; 54(12):1205-22.
PMID: 26177803
DOI: 10.1007/s40262-015-0299-6.
Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides.
Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S
Antimicrob Agents Chemother. 2014; 58(8):4555-64.
PMID: 24867984
PMC: 4135986.
DOI: 10.1128/AAC.02724-14.
Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T, Chu X, Evers R, Klopfer S, Caro L, Kothare P
Br J Clin Pharmacol. 2014; 78(3):587-98.
PMID: 24617605
PMC: 4243909.
DOI: 10.1111/bcp.12377.
Drug-drug interaction studies: regulatory guidance and an industry perspective.
Prueksaritanont T, Chu X, Gibson C, Cui D, Yee K, Ballard J
AAPS J. 2013; 15(3):629-45.
PMID: 23543602
PMC: 3691435.
DOI: 10.1208/s12248-013-9470-x.
Comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions".
Neuhoff S, Tucker G
Pharm Res. 2013; 30(6):1467-8.
PMID: 23504339
DOI: 10.1007/s11095-013-0988-5.
Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
Varma M, Lai Y, Kimoto E, Goosen T, El-Kattan A, Kumar V
Pharm Res. 2013; 30(4):1188-99.
PMID: 23307347
DOI: 10.1007/s11095-012-0956-5.